Is a complete CCCC research report available?

No complete published report is available for C4 Therapeutics, Inc. (CCCC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

C4 Therapeutics, Inc. (CCCC)

NASDAQ: CCCC · USD

$3.43

+0.22 (+6.7%)· Recorded snapshot

Market cap	421.4M
Revenue (ttm)	35M
Net income (ttm)	-101.4M
EPS (ttm)	-$0.91
Shares out	123M
Volume	3,940,220
Beta	3.08

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 35M
Net income (ttm): -101.4M
EPS (ttm): -$0.91
Market cap: 421.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Metric	Value
Amount currency	USD
CIK code	0001662579
Company name	C4 Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	12529R107
Earnings date	2026-11-09
Earnings time	bmo
Employees	104
Employees change	-6
Employees growth	-5.45%
Enterprise value	$177.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-10-02
Is primary listing	Yes
Is SPAC	No
ISIN number	US12529R1077
Last 10-K release date	2026-02-26
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$421.4M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$3.43
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	CCCC
U.S. state	Massachusetts
Website	https://www.c4therapeutics.com

Metric

Value

Amount currency

USD

CIK code

0001662579

Company name

C4 Therapeutics, Inc.

Country

United States

Country code

CUSIP number

12529R107

Earnings date

2026-11-09

Earnings time

bmo

Employees

104

Employees change

-6

Employees growth

-5.45%

Enterprise value

$177.8M

Exchange

NASDAQ

Financial currency

USD

Financial report date

2026-06-30

First seen

2026-05-09

Fiscal year end

December

Founded

2015

In index

RUSSELL2000

Industry

Biotechnology

IPO date

2020-10-02

Is primary listing

Yes

Is SPAC

ISIN number

US12529R1077

Last 10-K release date

2026-02-26

Last earnings date

2026-08-11

Last refreshed

2026-10-28

Last stock split type

Never

Market cap

$421.4M

Market cap category

Small-Cap

Next earnings date

2026-11-09

Options

Yes

Price

$3.43

Price currency

USD

Sector

Healthcare

SIC code

2836

Stock price date

2026-10-28

Symbol

CCCC

U.S. state

Massachusetts

Website

https://www.c4therapeutics.com

Metric	Value
Earnings yield	-26.52%
EV/Sales	5.04x
FCF / EV yield	-48.37%
FCF yield	-20.33%
Forward EV/Sales	7.51x
Forward P/S	17.87x
P/B ratio	1.6x
P/S ratio	11.99x
Price / tangible book value	1.7x
Sector forward P/E	23.56x
Sector P/E	50.13x

Metric

Value

Earnings yield

-26.52%

EV/Sales

5.04x

FCF / EV yield

-48.37%

FCF yield

-20.33%

Forward EV/Sales

7.51x

Forward P/S

17.87x

P/B ratio

1.6x

P/S ratio

11.99x

Price / tangible book value

1.7x

Sector forward P/E

23.56x

Sector P/E

50.13x

Metric	Value
EBIT margin	-288.34%
EBITDA margin	-283.82%
Gross margin	86.34%
Operating margin	-288.34%
Pretax margin	-289.09%
Profit margin	-289.44%
Profit per employee	$-975,154
Revenue per employee	$336,913
ROA	-19.25%
ROA (5Y)	-17.74%
ROCE	-32.47%
ROE	-48.14%
ROE (5Y)	-40.46%
ROIC	-23.34%
SBC / revenue	40.83%
Tax / revenue	0.35%

Metric

Value

EBIT margin

-288.34%

EBITDA margin

-283.82%

Gross margin

86.34%

Operating margin

-288.34%

Pretax margin

-289.09%

Profit margin

-289.44%

Profit per employee

$-975,154

Revenue per employee

$336,913

ROA

-19.25%

ROA (5Y)

-17.74%

ROCE

-32.47%

ROE

-48.14%

ROE (5Y)

-40.46%

ROIC

-23.34%

SBC / revenue

40.83%

Tax / revenue

0.35%

Metric	Value
EPS growth quarters	3
EPS growth years	2
Gross profit growth	105.56%
Net income growth quarters	3
Net income growth years	2
Revenue growth	2.33%
Revenue growth (Q)	2.75%
Revenue growth (QoQ)	7.95%
Revenue growth 3Y	29.78%
Revenue growth 5Y	0.65%
Revenue growth quarters	1
Revenue growth years	2

Metric

Value

EPS growth quarters

EPS growth years

Gross profit growth

105.56%

Net income growth quarters

Net income growth years

Revenue growth

2.33%

Revenue growth (Q)

2.75%

Revenue growth (QoQ)

7.95%

Revenue growth 3Y

29.78%

Revenue growth 5Y

0.65%

Revenue growth quarters

Revenue growth years

Metric	Value
Capital expenditures	$-523,000
Depreciation and amortization	$1.6M
EBIT	$-101M
EBITDA	$-99.4M
EPS	$-0.91
FCF per share	$-0.69
Financing cash flow	$160.6M
Free cash flow	$-85.4M
Free cash flow minus SBC	$-99.7M
Gross profit	$30.3M
Income taxes	$121,000
Investing cash flow	$-75.3M
Net cash flow	$453,000
Net income	$-101.4M
Operating cash flow minus SBC	$-99.2M
Operating income	$-101M
Revenue	$35M
Stock-based compensation	$14.3M

Metric

Value

Capital expenditures

$-523,000

Depreciation and amortization

$1.6M

EBIT

$-101M

EBITDA

$-99.4M

EPS

$-0.91

FCF per share

$-0.69

Financing cash flow

$160.6M

Free cash flow

$-85.4M

Free cash flow minus SBC

$-99.7M

Gross profit

$30.3M

Income taxes

$121,000

Investing cash flow

$-75.3M

Net cash flow

$453,000

Net income

$-101.4M

Operating cash flow minus SBC

$-99.2M

Operating income

$-101M

Revenue

$35M

Stock-based compensation

$14.3M

Metric	Value
Altman Z-Score	-1.87
Book value per share	$2.01
Debt / equity	0.23
Long-term assets	$96.5M
Long-term liabilities	$63.9M
Net cash (debt)	$243.6M
Net cash / market cap	57.98%
Net cash growth	52.2%
Net debt / equity	-0.99
Piotroski F-Score	4
Property, plant and equipment	$41.8M
Shareholders' equity	$247.3M
Tangible book value	$247.3M
Tangible book value per share	$2.01
Total assets	$359.4M
Total cash	$253.7M
Total debt	$56.9M
Total liabilities	$112.1M
WACC	18.68%

Metric

Value

Altman Z-Score

-1.87

Book value per share

$2.01

Debt / equity

0.23

Long-term assets

$96.5M

Long-term liabilities

$63.9M

Net cash (debt)

$243.6M

Net cash / market cap

57.98%

Net cash growth

52.2%

Net debt / equity

-0.99

Piotroski F-Score

Property, plant and equipment

$41.8M

Shareholders' equity

$247.3M

Tangible book value

$247.3M

Tangible book value per share

$2.01

Total assets

$359.4M

Total cash

$253.7M

Total debt

$56.9M

Total liabilities

$112.1M

WACC

18.68%

Metric	Value
Asset turnover	0.11
Current assets	$262.9M
Current liabilities	$48.2M
Current ratio	5.45
Net working capital	$-32.3M
Quick ratio	5.29
Working capital	$214.7M
Working capital turnover	0.18

Metric

Value

Asset turnover

0.11

Current assets

$262.9M

Current liabilities

$48.2M

Current ratio

5.45

Net working capital

$-32.3M

Quick ratio

5.29

Working capital

$214.7M

Working capital turnover

0.18

Metric	Value
Buyback yield / dilution	-58.3%
Dividend yield	0%
Shareholder yield	-58.3%

Metric

Value

Buyback yield / dilution

-58.3%

Dividend yield

Shareholder yield

-58.3%

Metric	Value
150-day SMA	$3.47
1D price change	6.7%
1M price change	14.93%
1M total return	14.93%
1W price change	8.04%
1W total return	8.04%
1Y price change	29.25%
1Y return CAGR	29.27%
1Y total return	29.25%
20-day SMA	$2.99
200-day SMA	$3.20
3M price change	-4.6%
3M total return	-4.6%
3Y price change	146.4%
3Y return CAGR	35.06%
3Y total return	146.4%
50-day SMA	$3.36
50-day SMA vs 200-day SMA	50over200
52-week high	$5.17
52-week high date	2026-06-30
52-week low	$1.69
52-week low date	2026-02-05
5Y price change	-92.4%
5Y return CAGR	-40.27%
5Y total return	-92.4%
6M price change	21.03%
6M total return	21.03%
All-time high	$51.21
All-time high date	2021-09-23
All-time low	$1.06
All-time low date	2023-12-06
Average true range (ATR)	$0.22
Average volume	2.9M
Beta (1Y)	2.39
Beta (2Y)	2.35
Beta (5Y)	3.08
Change from 52-week high	-33.75%
Change from 52-week low	102.66%
Change from all-time high	-93.31%
Change from all-time low	223.11%
Change from open	5.38%
Day's gap	1.25%
Dollar volume	$13.5M
High price	$3.53
Low price	$3.23
Monthly RSI	47.67
Open price	$3.25
Position in 52-week range	65%
Premarket change	1.71%
Premarket close	$3.21
Premarket price	$3.27
Premarket volume	33.3K
Previous close	$3.21
Price vs 150-day SMA	-1.3%
Price vs 20-day SMA	14.43%
Price vs 200-day SMA	7.13%
Price vs 50-day SMA	2.09%
Relative volume	1.39
Return from IPO open	-87.16%
Return from IPO price	-82.03%
RSI	59.02
Sharpe ratio	0.66
Sharpe ratio (3Y)	0.68
Sharpe ratio (5Y)	0.03
Sortino ratio	1.18
Sortino ratio (3Y)	1.66
Sortino ratio (5Y)	0.12
Volume	3.9M
Weekly RSI	51.98
YTD price change	79.32%
YTD total return	79.32%

Metric

Value

150-day SMA

$3.47

1D price change

6.7%

1M price change

14.93%

1M total return

14.93%

1W price change

8.04%

1W total return

8.04%

1Y price change

29.25%

1Y return CAGR

29.27%

1Y total return

29.25%

20-day SMA

$2.99

200-day SMA

$3.20

3M price change

-4.6%

3M total return

-4.6%

3Y price change

146.4%

3Y return CAGR

35.06%

3Y total return

146.4%

50-day SMA

$3.36

50-day SMA vs 200-day SMA

50over200

52-week high

$5.17

52-week high date

2026-06-30

52-week low

$1.69

52-week low date

2026-02-05

5Y price change

-92.4%

5Y return CAGR

-40.27%

5Y total return

-92.4%

6M price change

21.03%

6M total return

21.03%

All-time high

$51.21

All-time high date

2021-09-23

All-time low

$1.06

All-time low date

2023-12-06

Average true range (ATR)

$0.22

Average volume

2.9M

Beta (1Y)

2.39

Beta (2Y)

2.35

Beta (5Y)

3.08

Change from 52-week high

-33.75%

Change from 52-week low

102.66%

Change from all-time high

-93.31%

Change from all-time low

223.11%

Change from open

5.38%

Day's gap

1.25%

Dollar volume

$13.5M

High price

$3.53

Low price

$3.23

Monthly RSI

47.67

Open price

$3.25

Position in 52-week range

65%

Premarket change

1.71%

Premarket close

$3.21

Premarket price

$3.27

Premarket volume

33.3K

Previous close

$3.21

Price vs 150-day SMA

-1.3%

Price vs 20-day SMA

14.43%

Price vs 200-day SMA

7.13%

Price vs 50-day SMA

2.09%

Relative volume

1.39

Return from IPO open

-87.16%

Return from IPO price

-82.03%

RSI

59.02

Sharpe ratio

0.66

Sharpe ratio (3Y)

0.68

Sharpe ratio (5Y)

0.03

Sortino ratio

1.18

Sortino ratio (3Y)

1.66

Sortino ratio (5Y)

0.12

Volume

3.9M

Weekly RSI

51.98

YTD price change

79.32%

YTD total return

79.32%

Metric	Value
Float	94.5M
Float percentage	76.81%
Shares change (QoQ)	3.67%
Shares change (YoY)	58.3%
Shares held by insiders	1.04%
Shares held by institutions	86.71%
Shares outstanding	123M
Short % of float	42.75%
Short % of shares	32.84%
Short ratio	19.6 days

Metric

Value

Float

94.5M

Float percentage

76.81%

Shares change (QoQ)

3.67%

Shares change (YoY)

58.3%

Shares held by insiders

1.04%

Shares held by institutions

86.71%

Shares outstanding

123M

Short % of float

42.75%

Short % of shares

32.84%

Short ratio

19.6 days

C4 Therapeutics, Inc. (CCCC)

Price

Financial snapshot

Fair-value bridge

Latest news · CCCC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CCCC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CCCC

Frequently asked questions